Free Trial
NASDAQ:AVDL

Avadel Pharmaceuticals (AVDL) Stock Price, News & Analysis

Avadel Pharmaceuticals logo
$9.04 +0.15 (+1.69%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$8.91 -0.13 (-1.43%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Avadel Pharmaceuticals Stock (NASDAQ:AVDL)

Key Stats

Today's Range
$8.83
$9.05
50-Day Range
$8.53
$10.23
52-Week Range
$6.38
$17.30
Volume
1.60 million shs
Average Volume
1.23 million shs
Market Capitalization
$874.53 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.17
Consensus Rating
Buy

Company Overview

Avadel Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
49th Percentile Overall Score

AVDL MarketRank™: 

Avadel Pharmaceuticals scored higher than 49% of companies evaluated by MarketBeat, and ranked 557th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Avadel Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Avadel Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about Avadel Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Avadel Pharmaceuticals are expected to grow in the coming year, from ($0.51) to $0.06 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Avadel Pharmaceuticals is -33.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Avadel Pharmaceuticals is -33.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Avadel Pharmaceuticals has a P/B Ratio of 11.74. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Avadel Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    11.58% of the float of Avadel Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Avadel Pharmaceuticals has a short interest ratio ("days to cover") of 8.
  • Change versus previous month

    Short interest in Avadel Pharmaceuticals has recently decreased by 6.27%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Avadel Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Avadel Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    11.58% of the float of Avadel Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Avadel Pharmaceuticals has a short interest ratio ("days to cover") of 8.
  • Change versus previous month

    Short interest in Avadel Pharmaceuticals has recently decreased by 6.27%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Avadel Pharmaceuticals has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Avadel Pharmaceuticals this week, compared to 5 articles on an average week.
  • MarketBeat Follows

    Only 1 people have added Avadel Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Avadel Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 5.20% of the stock of Avadel Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    69.19% of the stock of Avadel Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Avadel Pharmaceuticals' insider trading history.
Receive AVDL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avadel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AVDL Stock News Headlines

Presidential Bombshell: $150T Resource to Be Released as soon as this Summer?
Something extraordinary is happening in Washington. For the first time in over a century, a sitting President could release a national treasure that's been tied up in red tape, for generations. I'm talking about a $150 trillion American asset that's scattered across all 50 states. While the mainstream media focuses on political theater, this story is quietly developing behind closed doors.
AVDL Avadel Pharmaceuticals plc - Seeking Alpha
See More Headlines

AVDL Stock Analysis - Frequently Asked Questions

Avadel Pharmaceuticals' stock was trading at $10.51 at the beginning of 2025. Since then, AVDL stock has decreased by 14.0% and is now trading at $9.04.

Avadel Pharmaceuticals PLC. (NASDAQ:AVDL) announced its quarterly earnings data on Wednesday, May, 7th. The company reported ($0.05) EPS for the quarter, beating analysts' consensus estimates of ($0.07) by $0.02. The firm's revenue for the quarter was up 93.2% compared to the same quarter last year.
Read the conference call transcript
.

Shares of AVDL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Avadel Pharmaceuticals investors own include Advanced Micro Devices (AMD), Bank of America (BAC), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Cisco Systems (CSCO) and Netflix (NFLX).

Company Calendar

Last Earnings
5/07/2025
Today
7/09/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AVDL
CIK
1012477
Employees
70
Year Founded
2015

Price Target and Rating

High Price Target
$30.00
Low Price Target
$12.00
Potential Upside/Downside
+101.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$48.83 million
Pretax Margin
-13.72%

Debt

Sales & Book Value

Annual Sales
$169.12 million
Price / Cash Flow
N/A
Book Value
$0.77 per share
Price / Book
11.74

Miscellaneous

Free Float
91,709,000
Market Cap
$874.53 million
Optionable
Optionable
Beta
1.42

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NASDAQ:AVDL) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners